Expectation to Exceed $88M in Revenue for 4th Quarter 2017

MiMedx Announces Expectation To Exceed Top End of Fourth Quarter Revenue Guidance Of $88 Million

MARIETTA, Ga., Nov. 30, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics…